Disc Medicine, Inc. Common Stock (IRON)
Disc Medicine, Inc. (IRON) is a clinical-stage biopharmaceutical company focused on developing therapies for serious and rare hematologic diseases. The company aims to address unmet medical needs through innovative drug discovery and development, with particular emphasis on conditions related to iron metabolism and anemia.
Company News
Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential drug commercialization and research efforts.
Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential commercialization of bitopertin and fund research and development.
Disc Medicine reported a Q2 2025 net loss of $55.2 million, with increased research and development expenses. The company is advancing clinical trials for bitopertin and other pipeline programs targeting blood disorders, with a strong cash position of $650 million to fund operations through 2028.
The article discusses upcoming events and earnings reports that investors should watch, including the consumer price index report, Federal Reserve minutes,...
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.